Table 2 Hazard Ratio of oro-tracheal intubation/death (OTI/death) in all population and according to PaO2/FiO2 at admission.

From: Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia

 

Unadjusted and adjusted marginal relative hazards of IOT/deatha

Unadjusted HR (95% CI)

p-value

Adjusted* HR (95% CI)

p-value

Adjusted** HR (95% CI)

p-value

All patients

  

No pLMWH

1.00

 

1.00

 

1.00

 

pLMWH

0.85 (0.35, 2.07)

0.727

0.89 (0.34, 2.29)

0.806

0.66 (0.28, 1.57)

0.352

Baseline PaO2/FiO2 ≤ 300 mmHg

  

No pLMWH

1.00

 

1.00

 

1.00

 

pLMWH

1.68 (0.65, 4.39)

0.287

1.49 (0.52, 4.23)

0.458

1.40 (0.51, 3.79)

 

Baseline PaO2/FiO2 > 300 mmHg

 

Interaction p-value 0.164

No pLMWH

1.00

 

1.00

 

1.00

 

pLMWH

0.33 (0.07, 1.48)

0.146

0.25 (0.02, 3.61)

0.310

0.27 (0.03, 2.18)

 
  1. pLMWH prophylactic dose of low molecular weight heparin.
  2. *Adjusted for time-fixed factors: age, gender, time from symptoms onset, comorbidities (cardiovascular diseases, hypertension, COPD/Asthma, diabetes), PaO2/FiO2 at admission.
  3. **Adjusted for time-fixed and time varying factors: age, gender, time from symptoms onset, comorbidities (cardiovascular diseases, hypertension, COPD/Asthma, diabetes), PaO2/FiO2 at admission, time-varying use of immune-therapy, antiviral and steroids and censoring using IPW.
  4. aInitiation of invasive mechanical ventilation or death.
Back to article page